PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

F. Sclafani, G. Brown, David Cunningham, A. Wotherspoon, D. Tait, C. Peckitt, J. Evans, S. Yu, L. Sena Teixeira Mendes, J. Tabernero, B. Glimelius, A. Cervantes, J. Thomas, R. Begum, J. Oates, I. Chau

Research output: Contribution to journalArticleResearchpeer-review

48 Citations (Scopus)


© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Background: EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). Design: We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Prognostic factors were also analysed. Results: A total of 269 patients were included. Of these, 91.1% completed NACT, 88.1% completed CRT and 240 (89.2%) underwent curative surgery (R0/R1). After a median follow-up of 71.9 months, 5-year progression-free survival (PFS) and OS were 66.4% and 73.3%, respectively. In the group of R0/R1 resection patients, 5-year relapse-free survival (RFS) and OS were 71.6% and 77.2%, respectively, with local recurrence occurring in 5.5% and distant metastases in 20.6% of cases. Significant prognostic factors after multivariate analyses included age, tumour grade and MRI extramural venous invasion (mrEMVI) at baseline, MRI tumour regression grade (mrTRG) after CRT, ypT stage after surgery and adherence to study treatment. mrTRG after NACT was associated with PFS (P = 0.002) and OS (P = 0.018) and appeared to stratify patients based on the incremental benefit from sequential CRT. Among the outcome measures considered, in the subgroup of R0/R1 resection patients, ypT and ypStage had the highest predictive accuracy for RFS (concordance index: 0.6238 and 0.6252, respectively) and OS (concordance index: 0.6094 and 0.6132, respectively). Conclusions: Administering NACT before CRT could be a potential strategy for high-risk LARC. In this setting, mrTRG after CRT is an independent prognostic factor, while mrTRG after NACT should be tested as a parameter for treatment selection in trials of NACT ± CRT. ypT stage may be a valuable surrogate end point for future phase II trials investigating intensified neoadjuvant treatments in similar patient populations.
Original languageEnglish
Pages (from-to)1557-1565
JournalAnnals of Oncology
Issue number8
Publication statusPublished - 1 Aug 2016


  • Chemoradiotherapy
  • Locally advanced rectal cancer
  • MR tumour regression grade
  • Neoadjuvant chemotherapy
  • Pooled analysis


Dive into the research topics of 'PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer'. Together they form a unique fingerprint.

Cite this